The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors

MLA

Mark-Alexander Schwarzbich, et al. “The Immune Inhibitory Receptor Osteoactivin Is Upregulated in Monocyte-Derived Dendritic Cells by BCR–ABL Tyrosine Kinase Inhibitors.” Cancer Immunology, Immunotherapy, vol. 61, Aug. 2011, pp. 193–202. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f99f2f90e0d52f8311146a03c22007e7&authtype=sso&custid=ns315887.

APA

Mark-Alexander Schwarzbich, Helmut R. Salih, Julia Salih, Frank Grünebach, Michael Gutknecht, Susanne M Rittig, & Peter Brossart. (2011). The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors. Cancer Immunology, Immunotherapy, 61, 193–202.

Chicago

Mark-Alexander Schwarzbich, Helmut R. Salih, Julia Salih, Frank Grünebach, Michael Gutknecht, Susanne M Rittig, and Peter Brossart. 2011. “The Immune Inhibitory Receptor Osteoactivin Is Upregulated in Monocyte-Derived Dendritic Cells by BCR–ABL Tyrosine Kinase Inhibitors.” Cancer Immunology, Immunotherapy 61 (August): 193–202. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f99f2f90e0d52f8311146a03c22007e7&authtype=sso&custid=ns315887.